Introduction
============

As the most lethal gynecological cancer world-wide, the incidence of ovarian cancer has increased [@B1], [@B2]. Statistics indicate that 85\~90% of patients with ovarian cancer have epithelial ovarian cancer, and 75% of those patients have serous ovarian cancer [@B3], [@B4]. It is well-known that tumor stage, histological grade, and residual tumor size are significant prognostic factors for ovarian cancer patients [@B5]. Moreover, recent studies suggest that the mutation status of *BRCA1/2* correlates with patient prognosis and the chemosensitivity of ovarian cancer, and especially serous ovarian cancer [@B6]. Based on our increased knowledge of how molecular heterogeneity affects ovarian cancer progression, it has been suggested that prognostic biomarkers be included in any clinical analysis of ovarian tumors [@B7].

As a mechanism for maintaining cellular homeostasis, autophagy is a process that degrades cellular components under conditions of stress or nutrient deprivation [@B8], [@B9], and therefore plays an important role in numerous biological and pathological processes, including neurodegenerative diseases, cardiomyopathy and cancer [@B9], [@B10]. However, the role of autophagy in tumorigenesis remains controversial.

Previous studies have shown that autophagy can either promote or suppress tumor cell survival at different stages of cancer development [@B11]. During the early stages of cancer, autophagy promotes the degradation of damaged proteins or organelles to alleviate cellular damage and chromosomal instability, and thus suppresses cancer progression [@B12]-[@B14]. However, once the cancer has formed, autophagy allows tumor cells to survive under stressful conditions, and thus promotes tumor progression [@B15]-[@B17].

The relationship between autophagy and ovarian cancer has been previously reported. For instance, autophagy was shown to promote chemoresistance and help maintain the stemness of ovarian cancer stem cells [@B18]. Notably, previous studies have focused on exploring the relationship between autophagy and ovarian cancer progression; however, large-scale expression data has rarely been used to investigate the role of autophagy in ovarian cancer progression and prognosis.

Because high-throughput expression data is now available, it has become feasible to use global gene expression data for analyzing the relationship between autophagy-related gene expression and the clinical outcomes of ovarian cancer patients. In this study, we detected an autophagy-related risk signature that contains eight autophagy-related genes. This signature can be used to independently and accurately predict the prognostic value for serous ovarian cancer, and is closely correlated with the mutation status of *BRCA1/2*. Broadly speaking, our study demonstrates that autophagy plays an essential role in cancer, and suggests autophagy-related genes as promising prognostic biomarkers for serous ovarian cancer.

Materials and methods
=====================

Autophagy-related gene set
--------------------------

We searched the HADb (Human Autophagy Database) to identify 234 genes that had been described in literature as being involved in the autophagy process [@B19]. In addition, 394 autophagy-related genes were obtained from the gene set (GO_autophagy, M12441) in the Molecular Signatures Database v4.0 [@B20].

Patient samples
---------------

Firehose was used to generate a normalized gene expression dataset and clinical information pertinent to ovarian serous cystadenocarcinoma patients from The Cancer Genome Atlas (TCGA) database. A full mutation dataset of corresponding patients was obtained from cBioPortal [@B21], [@B22]. The nine independent microarray serous ovarian cancer cohorts produced by the HGU133 Plus 2 platform were extracted from the Gene Expression Omnibus (GEO) database (accession number: GSE14407, GSE38666, GSE54388, GSE27651, GSE18520, GSE40595, GSE32062, GSE26193, and GSE51088 [@B23]-[@B31]. The Robust Multi-array Average method was used to normalize raw microarray datasets [@B32]. The ComBat method was used to remove any batch effects, and thereby eliminate discrepancies between different datasets [@B33]. When more than one probe matched the same gene ID, the probe with the largest expression value was used for our study. GSE26193 and GSE51088 were selected as our independent validation cohorts because they are the largest datasets containing information on overall survival among the nine different datasets. Overall, 529 samples from microarray of TCGA were used as a discovery cohort, 295 samples from the RNAseq of TCGA were used as an internal validation cohort, 79 samples from GSE26193 and 106 samples from GSE51088 were used as two independent external validation cohorts.

Procedures
----------

The R programming language was used to perform a principle components analysis for the purpose of investigating the distinct gene expression patterns of samples.

An R package survivalROC was used to create receiver operating characteristic (ROC) curves that were used to evaluate the sensitivity and specificity of survival. Next, area under the curve (AUC) values was calculated according to the ROC curves.

GSEA was used to perform the gene set enrichment analysis [@B20]. A normalized enrichment score (NES) and false discovery rate (FDR) were used to determine statistical significance.

Statistical analysis
--------------------

A univariate Cox proportional hazard regression analysis was used to evaluate the association between overall survival time and gene expression values obtained from the autophagy-related gene set in the test cohort. The prognostic value of a gene was considered statistically significant when the *p*-value was \< 0.01. Next, a multivariate Cox proportional hazards regression analysis was performed using the pool of candidate prognostic genes. The Akaike information criterion (AIC) was used to select the most appropriate model [@B34]. By weighting the estimated Cox regression coefficients, the eight-gene risk signature was constructed [@B35]. Patients were classified into high-risk and low-risk groups according to their risk score, and using the median score as the cutoff point. The Kaplan-Meier method and log-rank test were used to estimate the overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) times of patients. Independent prognostic factors were identified using the multivariate Cox proportional hazards regression model, and hazard ratios (HR) were calculated using the Cox regression model. The prediction accuracy of this risk model was determined by a time-dependent ROC analysis. A prognostic nomogram was created for OS based on the Cox proportional hazard regression model. A concordance index (C-index) was calculated to determine the performance of the nomogram. The nomogram and calibration plot were created using the rms package of R software. The Chi-square test was used to evaluate the correlation between *BRCA1/2* mutation status and the autophagy-related signature. R software (version 3.4.1) was used to perform the bioinformatics analysis. All tests were two-tailed and *p*-values \< 0.05 were considered statistically significant. All data were analyzed using GraphPad Prism 7 software (GraphPad Software Inc., La Jolla, CA, USA). Differences in clinicopathologic parameters between high-risk and low-risk groups were tested by Students t test or the X^2^ test.

Results
=======

Distinct autophagy-related phenotype expression patterns in normal ovaries and serous ovarian cancer
----------------------------------------------------------------------------------------------------

The general process of our study is described as Fig. [1](#F1){ref-type="fig"}a. A total of 117 serous ovarian cancer tissues and 52 normal ovarian tissues with mRNA expression data were obtained from 7 GEO datasets. The autophagy-related gene set included 546 genes from the Human Autophagy Database and another gene set (GO_autophagy, M12441) from the Molecular Signatures Database, v4.0. A principal components analysis comparing serous ovarian cancer tissues with normal ovarian tissues based on their autophagy-related genes showed two significantly different distribution patterns. Normal ovarian samples were distributed on the left side, while samples of serous ovarian cancer were distributed on the right side, suggesting distinctly different regulatory roles for autophagy in normal ovaries and serous ovarian cancer (Fig. [1](#F1){ref-type="fig"}b).

Identification of an autophagy-related risk signature for the prognosis of serous ovarian cancer
------------------------------------------------------------------------------------------------

After reviewing the distinct autophagy-related gene expression pattern found in serous ovarian cancer when compared with the pattern found in normal ovaries, we investigated the role that autophagy might play in serous ovarian cancer, and identified an autophagy-related risk signature that might be useful for establishing the prognosis. A Cox regression analysis was performed to investigate the prognostic value of autophagy-related genes found in 529 serous ovarian cancer patients as listed in the TCGA microarray dataset. Twelve genes (*PRKG1, FGF7, WDR45L, NRG4, BLOC1S1, IL24, PEX3, CDKN1B, CD93, SIRT2, PDK4,* and *SLC22A3*) were found to be significantly associated with OS in serous ovarian cancer patients (*p* \< 0.01, Table [1](#T1){ref-type="table"}). The AIC was used to select the most appropriate model, which was identified as a model comprised of eight different genes (*BLOC1S1, IL24, NRG4, PDK4, PEX3, PRKG1, SIRT2,* and *WDR45L*). Among the eight genes, four genes (*BLOC1S1, IL24, NRG4,* and*WDR45L*) were identified as protective factors (HR \< 1), while the other four genes (*PKD4, PEX3, PRKG1,* and *SIRT2*) were identified as risk factors (HR \> 1).

We then used a multivariate Cox regression model to develop the following autophagy-related risk signature associated with the survival of serous ovarian cancer patients [@B36].

We then calculated the risk score of each patient according to their eight-gene expression signature, and used the median risk value as a cutoff point for classifying patient into a high-risk group (n = 264) and a low-risk group (n = 265), respectively. Patients in the high-risk group had a shorter overall survival time than patients in the low-risk group (median time = 2.84 years vs. 4.72 years, *p* \< 0.001, Fig. [2](#F2){ref-type="fig"}a). In addition, we also found that patients in the high-risk group had shorter DFS times (median time = 1.15 years vs. 1.77 years, *p* \< 0.001, Fig. [2](#F2){ref-type="fig"}b).

Serous ovarian cancer cases were divided into high-risk and low-risk groups according to the median eight-gene risk score (Fig. [2](#F2){ref-type="fig"}c). Protective and risky genes showed distinct expression patterns according to the risk value. High-risk patients expressed higher levels of risky genes (*PKD4, PEX3, PRKG1,* and *SIRT2*), while low-risk patients expressed higher levels of protective genes (*BLOC1S1, IL24, NRG4,* and*WDR45L*).

ROC curves for 3-year survival were used to reveal the predictive performance of the eight-gene risk signature (Fig. [2](#F2){ref-type="fig"}d). The 3-year AUC of our signature was 0.703, which was obviously higher than that of age (AUC = 0.626), neoplasm cancer status (AUC = 0.615), residual tumor size (AUC = 0.603), tumor stage (AUC = 0.581), and tumor grade (AUC = 0.544). These results indicated that the ability to predict survival of serous ovarian cancer patients was improved by using the eight-gene risk signature when compared to using clinical factors.

Due to such different prognostic outcomes, we sought to investigate possible differences between the high-risk and low-risk groups by using GSEA, which verified an enhanced autophagy-related signature in the high-risk group (Fig. [2](#F2){ref-type="fig"}e). Therefore, we propose the existence of an intense regulatory role for autophagy in high-risk serous ovarian patients.

Associations between the autophagy-related risk signature and clinicopathologic features in serous ovarian cancer patients
--------------------------------------------------------------------------------------------------------------------------

An analysis was performed to explore associations between various clinical parameters and our risk signature in serous ovarian cancer patients (Table [2](#T2){ref-type="table"}). Results showed that the signature was significantly associated with age (*p* = 0.015), Karnofsky performance status (KPS, *p* \< 0.0001), and neoplasm cancer status (*p* = 0.0443). Additionally, we found that the signature was only marginally associated with therapy outcome (*p* = 0.0512) and therapy type (*p* = 0.0736).

Application of the autophagy-related signature in stratified serous ovarian cancer cohorts
------------------------------------------------------------------------------------------

In order to investigate the prognostic value of the risk signature in stratified cohorts, patients were classified by residual tumor size, age, and lymphatic invasion status. In all cohorts, the high-risk group had shorter OS (Fig. [3](#F3){ref-type="fig"}) and DFS times (Fig. [4](#F4){ref-type="fig"}) than the low-risk group. These results suggest that classification of the autophagy-related risk signature can be used to precisely identify patients with the poor prognosis, without the consideration of clinical parameters.

The autophagy-related signature is an independent prognostic factor for serous ovarian cancer patients
------------------------------------------------------------------------------------------------------

We performed univariate Cox and multivariate Cox regression analyses of data in the TCGA dataset in order to investigate whether the autophagy-related signature was an independent factor correlated with OS and DFS (Table [3](#T3){ref-type="table"}). The univariate Cox analysis showed that the autophagy-related signature, age, tumor stage, residual tumor size, and *BRCA1/2* mutation status were all correlated with the overall survival of serous ovarian cancer patients; therefore, those factors were included in a multivariate Cox analysis. Moreover, the risk signature, residual tumor size, and *BRCA1/2* mutation status each showed a significant correlation with DFS. Thus our results indicated that the autophagy-related signature might be an independent prognostic factor of OS and DFS when adjusted by those factors.

Validation of the eight-gene autophagy-related prognostic signature using three independent cohorts
---------------------------------------------------------------------------------------------------

To validate the eight-gene risk signature in other datasets, we calculated the risk score for each patient in the TCGA RNAseq dataset as an internal validation, in the GSE26193 and GSE51088 datasets as the independent external validations using same formula. The patients in these three datasets were then divided into a high-risk and a low-risk group based on the median risk score. As expected, the survival curves showed that in the TCGA RNAseq dataset, which including 295 patients, the overall survival time and disease-free survival time were much lower in the high-risk group (OS, median = 2.90 years vs. 4.33 years, *p* \< 0.001, Fig. [5](#F5){ref-type="fig"}a; DFS, median = 1.22 years vs. 1.98 years, *p* \< 0.001,Fig. [5](#F5){ref-type="fig"}b). While there was no DFS information in GSE26193, we used the progression-free survival time to create survival curves. Similarly, in dataset GSE26193, which including 79 patients, the high-risk patients had lower overall survival time and progression-free survival time than the low-risk patients (OS, median = 2.42 years vs. 3.90 years, *p* = 0.026, Fig.[5](#F5){ref-type="fig"}c; PFS, median = 1.66 years vs. 1.87 years, *p* = 0.042, Fig. [5](#F5){ref-type="fig"}d). In addition, we also found in dataset GSE51088, which including 106 patients, the overall survival time were much lower in the high-risk group (OS, median = 3.93 years vs. 5.28 years, *p* = 0.034, Fig. [5](#F5){ref-type="fig"}e).

We next arrayed the patients according to the risk score in the validation cohorts. The heat map displayed the expression patterns of the eight autophagy-related prognostic genes in the two groups. As expected, in the TCGA RNAseq (Fig. [5](#F5){ref-type="fig"}h), GSE26193 (Fig.[5](#F5){ref-type="fig"}f) and GSE51088 (Fig. [5](#F5){ref-type="fig"}g) datasets, the expression levels of the four protective genes were down-regulated in the high-risk group, while the risk factor genes were expressed at high levels. In contrast, those genes showed an opposite expression pattern in the low-risk group.

Consistent with the finding in the test cohort, the autophagy-related signature was further validated by the TCGA RNAseq, GSE26193 and GSE51088 datasets, confirming its power to independently predict the prognosis (Table [4](#T4){ref-type="table"}). All these three cohorts validated that this novel autophagy-related signature could work as an independent predictor for the prognosis of serous ovarian cancer.

Nomogram development for the prediction of prognostic risk
----------------------------------------------------------

In order to provide clinicians with a quantitative approach for predicting cancer survival, we assembled a nomogram that integrated both the risk signature and various clinicopathologic risk factors. The nomogram was constructed to estimate 1-, 2-, 3-, 4-, and 5 -year survival probabilities, and it showed that the signature risk score was the most essential factor among the different variables analyzed (Fig. [6](#F6){ref-type="fig"}a). A C-index was calculated to estimate the performance of this nomogram (Fig. [6](#F6){ref-type="fig"}b). The C-index of our nomogram was 0.778. A calibration plot showed optimal agreement when compared with an ideal model.

Association between the risk signature and gene mutation status, and especially *BRCA1/2* mutation status
---------------------------------------------------------------------------------------------------------

The ten genes (*BRCA1, BRCA2, CSMD3, FAT3, HMCN1, MUC16, RYR2, TP53, TTN,* and *USH2A*) with the highest mutation rates in 293 patients were selected for further study (Fig. [7](#F7){ref-type="fig"}a). The association between autophagy-related signature and each of those ten genes is shown in Table [5](#T5){ref-type="table"}. The data indicated that mutation of the *BRCA1* gene (*p* = 0.0359) helped to extend the survival of serous ovarian cancer patients, while mutation of the *BRCA2* (*p* = 0.0691) or *TTN* (*p* = 0.0884) gene had a marginally favorable effect on survival. The mutation status of *BRCA1/2* was recently reported to be an important favorable survival predictor in ovarian cancer [@B6]. Therefore, we further investigated the effect of combined *BRCA1* and *BRCA2* gene mutations. As expected, the *BRCA1/2* mutation status was significantly correlated with our risk signature (*p* = 0.0062). Therefore, the patients were arranged according to their risk scores. The genes in our autophagy-related signature showed distinct expression patterns according to the *BRCA1/2* mutation status (Fig. [7](#F7){ref-type="fig"}b).

Discussion
==========

Ovarian cancer is a progressive disease that urgently needs reliable prognostic markers that can aid in its diagnosis and treatment. Computational models have recently been used to explore possible mRNA and non-coding RNA biomarkers for ovarian cancer. Furthermore, numerous studies have focused on the role that autophagy plays in tumorigenesis and the results produced by cancer therapies. While most studies of autophagy-related genes have used cell lines or animal models, our current study used high-throughput expression profiling of autophagy-related genes to investigate the progression and outcomes of serous ovarian cancer patients.

As a novel therapeutic method, the influence of autophagy on cancer has been discussed for several years. Sui et al. suggested that autophagy might influence how patients respond to chemoradio-therapy [@B37]. In our study, we first examined differences in the autophagy status of normal ovarian tissues and serous ovarian cancer tissues, and then explored the role that autophagy might play in serous ovarian cancer. Although the controversial and complex role played by autophagy in cancer development has been widely discussed during the past decade, researchers have not reached a conclusion. Therefore, development of a meaningful autophagy-related risk signature should not only benefit the science of disease prognosis, but also provide clinicians with a rationale for using autophagy targeting therapies for treating serous ovarian cancer patients. In this study, we profiled an eight-gene autophagy-related model gene signature that could predict the prognosis of serous ovarian cancer, which was further validated in the GEO database. As described in GSEA, high-risk group showed positive regulation of autophagy, which suggested that the autophagy level might be increased in high-risk group with worse prognostic outcomes. As we all known, cisplatin resistant ovarian cancer cells showed higher autophagy level compared with the cisplatin sensitivity ovarian cancer cells [@B38], which is in accordance with our results. Previous studies have demonstrated that patients with *BRCA1/2* gene mutations had higher chemosensitivity and better prognosis [@B6], while our results showed that high-risk group correlated with lower possibility of *BRCA1/2* gene mutations and higher autophagy level, which is in accordance with the conclusion that chemoresistance of ovarian cancer cells correlated with higher autophagy level. Kwon et al performed a cDNA analysis which showed that among four high-risk genes, *PDK4* was greatly overexpressed in ovarian cancer stem cells when compared with parental ovarian cancer cells [@B39]. Additionally, S Sun et al demonstrated that *FAM210B* expression loss led to the regulation of *PDK4* expression, which is significantly associated with tumor metastasis and decreased survival of ovarian cancer patients [@B40]. Knockdown of *SIRT2* was also found to be associated with ovarian cancer cell proliferation, migration, and invasion [@B41]. However, with regards to other genes, most studies have focused on their role in autophagy rather than ovarian cancer. Zhao et al. reported that autophagy contributed to the resistance of osteosarcoma cells to doxorubicin [@B42], while *IL24* could suppress autophagy, and thus reverse the multiple drug resistance of osteosarcoma [@B43]. Moreover, other studies have reported that high levels of *PEX3* expression can induce pexophagy, and that ubiquitination of *PEX3* is not essential for pexophagy [@B44].

*BRCA1/2* mutation status has been well studied as an important molecular marker for ovarian cancer. Ovarian cancer patients with *BRCA1/2* mutations have shorter survival times and higher degrees of chemosensitivity [@B6]. It is known that PARP inhibitors can inhibit the proliferation of cancer cells with *BRCA1/2* mutations. Moreover, recent studies have demonstrated that the PARP inhibitor can induce autophagy in *BRCA1* or *BRCA2* mutated breast cancer cells, and that inhibition of autophagy results in the partial inhibition of PARP inhibitor induced apoptosis [@B45]. These results suggest that autophagy plays an essential role in regulating *BRCA1/2* mutated cancer cell proliferation and apoptosis. Coincidentally, another study showed significant decreases in serum *LC3* and *Bcl-2* expression levels in breast cancer patients with the 5382insC *BRCA1* mutation [@B46]. In our current study, we found a close correlation between *BRCA1/2* mutation status and the risk signature for ovarian cancer, which suggests that autophagy might contribute to the *BRCA1/2* mutations found in serous ovarian cancer cells; however, the precise mechanism for this contribution remains unknown. Thus additional studies should be considered to further explore the role played by autophagy in *BRCA1/2* mutated serous ovarian cancer.

Further studies showed that our signature was an independent prognostic factor for serous ovarian cancer, which suggests that autophagy status might serve as an accurate prognostic indicator. In this study, patients with higher risk scores significantly showed worse prognosis. Our nomogram demonstrated that the risk score associated with the signature for each patient was the most important variable, indicating its significant meaning when predicting the prognosis of serous ovarian cancer patients. Interestingly, by building this nomogram, we found that American Indian and Asian patients showed poorer prognosis than White patients. As we all known, patients with old ages, visible residual tumor sizes, higher FIGO stages and tumor grades all showed worse prognostic outcomes, which is in accordance with our results. Additionally, patients with *BRCA1/2* gene mutations showed higher chemosensitivity and thus caused better prognosis [@B6]. Thus, this nomogram provided an individualized thorough estimate of survival, rather than using specific covariates. Moreover, perfect agreement was seen between actual observations and predictions in the calibration plot. Thus, the eight-gene signature could precisely predict the prognosis for serous ovarian cancer patients.

The advantage of our study is that we performed a systematic analysis of microarray data and RNAseq data, which provided a robust statistical approach for exploring the role of autophagy in serous ovarian cancer. Although the eight-gene signature allowed for a practical independent prognosis for serous ovarian cancer, our study does have certain limitations. First, only autophagy-related genes were included in the study, and the risk signature does not represent the entire gene transcription profile associated with serous ovarian cancer. Second, our study is restricted because it is retrospective, and our results should be validated in prospective investigations.

In summary, we developed an autophagy-related gene expression model that could independently predict the overall survival of serous ovarian cancer patients. Furthermore, our results suggest that use of a targeted autophagy therapy might be a promising future strategy for treating serous ovarian cancer. Further investigations into the molecular mechanisms of autophagy will demonstrate how autophagy affects survival, and provide new suggestions for treating ovarian cancer patients. Thus, our eight-gene autophagy-related signature may predict the overall survival of serous ovarian cancer patients, and also guide the therapeutic approaches used for those patients.

Supported by grant from the Shenyang Science and Technology Bureau (award number: LNCCC-A01-2015)

AIC

:   Akaike information criterion

AUC

:   area under the curve

C-index

:   concordance index

DFS

:   disease-free survival

FDR

:   false discovery rate

GEO

:   Gene Expression Omnibus

GSEA

:   gene set enrichment analysis

HADb

:   Human Autophagy Database

HR

:   hazard ratio

KPS

:   Karnofsky performance status

NES

:   normalized enrichment score

OS

:   overall survival

PFS

:   progression-free survival

ROC

:   receiver operating characteristic

TCGA

:   The Cancer Genome Atlas.

![**(a)** Flowchart for the study; **(b)** Principle components analysis of autophagy-related genes in normal ovaries and serous ovarian cancer.](jcav09p4058g001){#F1}

![Kaplan-Meier curves for OS (a) and DFS (b) in the high-risk and low-risk groups when stratified by the autophagy-related signature; (c) Hierarchical clustering of high-risk and low-risk patients expressing the eight genes. Red indicates higher expression and green indicates lower expression; (d) ROC analysis at 3-year of overall survival for the eight-gene signature and classical clinicopathologic parameters in the TCGA cohort; (e) A GSEA comparing the autophagy phenotypes in high-risk and low-risk groups.](jcav09p4058g002){#F2}
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![Based on median risk score, the eight-gene risk signature divided patients into high-risk and low-risk groups with distinct prognosis in the TCGA RNAseq cohort (a-b), GSE26193 cohort (c-d), and GSE51088 cohort (e); (f-h) Hierarchical clustering of high-risk and low-risk patients expressing the eight genes in GSE26193 (f), GSE51088 (g), and TCGA RNAseq (h). Red indicates higher expression and green indicates lower expression.](jcav09p4058g005){#F5}

![**(a)** Prognostic nomogram for serous ovarian cancer patients; (b) Calibration curves for the nomogram at different time points.](jcav09p4058g006){#F6}

![**(a)** Associations between the risk signature and *BRCA1/2* mutation status with its related genes; **(b)** Top ten genes with highest mutation rates in serous ovarian cancer patients of TCGA microarray database](jcav09p4058g007){#F7}

###### 

Top 12 genes significantly associated with the survival time of patients in the training dataset (N = 529)

  Gene name   HR         *P*-value
  ----------- ---------- -----------
  PRKG1       1.425733   0.001275
  FGF7        1.2575     0.001398
  WDR45L      0.764353   0.002558
  NRG4        0.858855   0.00393
  BLOC1S1     0.707778   0.004328
  IL24        0.618953   0.004421
  PEX3        1.292997   0.00461
  CDKN1B      1.280662   0.00528
  CD93        1.195552   0.005346
  SIRT2       1.377175   0.006193
  PDK4        1.188561   0.006719
  SLC22A3     1.246166   0.006826

HR: hazard ratio

###### 

Clinical characteristics of serous ovarian cancer patients by autophagy-related signature.

  Characteristics           High-risk (n = 264)          Low-risk (n = 265)   *p*-value     
  ------------------------- ---------------------------- -------------------- ------------- --
  Age                                                                         0.0015        
                            Mean (years)                 61.20                58.02         
  FIGO stage                                                                  0.3899        
                            I                            10 (3.8%)            5 (1.9%)      
  II                        11 (4.2%)                    14 (5.3%)                          
  III                       197 (74.6%)                  211 (79.6%)                        
  IV                        44 (16.7%)                   34 (12.8%)                         
  NA                        2 (0.7%)                     1 (0.4%)                           
  Residual tumor size                                                         0.3594        
                            No macroscopic               53 (20.1%)           54 (20.4%)    
  1-10nm                    118 (44.7%)                  114 (43.0%)                        
  11-20nm                   14 (5.3%)                    20 (7.5%)                          
  \>20nm                    56 (21.2%)                   44 (16.6%)                         
  NA                        23 (8.7%)                    33 (12.5%)                         
  Lymphatic invasion                                                          0.8329        
                            Yes                          67 (25.4%)           65 (24.5%)    
                            No                           36 (13.6%)           41 (15.5%)    
                            NA                           161 (61%)            159 (60.6%)   
  KPS                                                                         \<0.0001      
                            40                           0 (0.0%)             2 (0.7%)      
                            60                           6 (2.3%)             9 (3.4%)      
                            80                           6 (2.3%)             34 (12.8%)    
                            100                          1 (0.3%)             6 (2.3%)      
                            NA                           251 (95.1%)          214 (80.8%)   
  Venous invasion                                                             0.4883        
                            Yes                          42 (15.9%)           43 (16.2%)    
                            No                           38 (14.4%)           29 (10.9%)    
                            NA                           184 (69.7%)          193 (72.9%)   
  Therapy type                                                                0.0736        
                            Chemotherapy                 216 (81.8%)          237 (89.4%)   
                            Immunotherapy                3 (1.1%)             2 (0.8%)      
                            Hormone therapy              3 (1.1%)             4 (1.5%)      
                            Targeted molecular therapy   8 (3.1%)             2 (0.8%)      
                            NA                           34 (12.9%)           20 (7.5%)     
  Therapy outcome                                                             0.0512        
                            Complete remission           132 (50.0%)          165 (62.3%)   
                            Partial remission            35 (13.3%)           24 (9.1%)     
                            Progressive disease          18 (6.8%)            18 (6.8%)     
                            Stable disease               19 (7.2%)            11 (4.2%)     
                            NA                           60 (22.7%)           47 (17.7%)    
  Neoplasm cancer status                                                      0.0443        
                            With tumor                   178 (67.4%)          155 (58.5%)   
                            Tumor free                   55 (20.8%)           80 (30.2%)    
                            NA                           31 (11.8%)           30 (11.3%)    
  New neoplasm event type                                                     0.7736        
                            Recurrence                   128 (48.5%)          135 (51.0%)   
                            Progression of disease       12 (4.5%)            15 (5.7%)     
                            Locoregional disease         3 (1.1%)             3 (1.1%)      
                            Metastatic                   1 (0.4%)             0 (0.0%)      
                            NA                           120 (45.5%)          112 (42.2%)   
  Radiation therapy                                                           0.1020        
                            Yes                          4 (1.5%)             1 (0.4%)      
                            No                           250 (94.7%)          260 (98.1%)   
                            NA                           10 (3.8%)            4 (1.5%)      
  Tumor grade                                                                 0.7955        
                            G1                           2 (0.7%)             4 (1.5%)      
                            G2                           33 (12.5%)           33 (12.5%)    
                            G3                           223 (84.5%)          221 (83.4%)   
                            G4                           0 (0.0%)             1 (0.4%)      
                            NA                           6 (2.3%)             6 (2.2%)      
  Race                                                                        0.4475        
                            White                        227 (86.0%)          231 (87.2%)   
                            Black or African American    12 (4.6%)            11(4.2%)      
                            Asian                        8 (3.0%)             11 (4.2%)     
                            American Indian              3 (1.1%)             0 (0.0%)      
                            NA                           14 (5.3%)            12 (4.4%)     

KPS: Karnofsky performance score

###### 

Univariate and multivariate Cox regression analyses of the autophagy-related signature and clinical characteristics predictive of overall survival and disease-free survival.

  Variable                                    Overall survival   Disease-free survival                                                                                                           
  ------------------------------------------- ------------------ -------------------------------- ------------ -------------------------------- ------- -------------------------------- ------- --------------------------------
                                              Univariate         Multivariate                     Univariate   Multivariate                                                                      
                                              HR                 ![](jcav09p4058i002.jpg)-value   HR           ![](jcav09p4058i003.jpg)-value   HR      ![](jcav09p4058i004.jpg)-value   HR      ![](jcav09p4058i005.jpg)-value
  Eight-gene signature                        0.414              \<0.001                          0.463        \<0.001                          0.488   \<0.001                          0.599   0.007
  (low-risk vs high-risk)                                                                                                                                                                        
  Age (old age vs young age)                  1.019              0.001                            1.016        0.033                            1.012   0.058                                    
  Tumor grade (G3-G4 vs G1-G2)                1.180              0.056                                                                          1.219   0.051                                    
  FIGO stage                                  1.658              0.003                            1.837        0.040                            1.432   0.084                                    
  (stage III-IV vs stage I-II)                                                                                                                                                                   
  Residual tumor size                         0.436              \<0.001                          0.578        0.037                            0.478   0.002                            0.487   0.016
  (no macroscopic vs visible macroscopic)                                                                                                                                                        
  *BRCA1/2* mutation stage                    2.021              0.001                            1.874        0.004                            1.752   0.020                            1.602   0.065
  (no mutation vs mutation)                                                                                                                                                                      
  Lymphatic invasion                          1.422              0.114                                                                          1.491   0.148                                    
  (invasion vs no invasion)                                                                                                                                                                      
  Venous invasion (no invasion vs invasion)   0.973              0.917                                                                          0.714   0.311                                    

HR: hazard ratio

###### 

Univariate and multivariate Cox regression analyses of the autophagy-related signature and clinical characteristics predictive of OS, DFS and PFS in each validation cohort

                                                        Overall survival             Disease-free survival            Progression-free survival                                                                                 
  ----------------------------------------------------- ------------------ --------- ----------------------- -------- --------------------------- -- ------- --------- -- ------- ------- -- ------- ------- -- ------- ------- --
  TCGA RNAseq cohort (n = 295)                                                                                                                                                                                                  
  Eight-gene signature (low-risk vs high-risk)          0.477              \<0.001                           0.468    \<0.001                        0.491   \<0.001      0.517   0.001                                         
  Age (old age vs young age)                            1.022              0.003                             1.016    0.033                          1.014   0.058                                                              
  Tumor grade (G3-G4 vs G1-G2)                          1.663              0.038                             1.777    0.120                          1.337   0.051                                                              
  FIGO stage (stage III-IV vs stage I-II)               1.487              0.057                                                                     1.216   0.084                                                              
  Residual tumor size (visible vs no macroscopic)       1.587              0.054                                                                     1.968   0.002        1.889   0.023                                         
  *BRCA 1/2* mutation stage (mutation vs no mutation)   0.613              0.033                             0.758    0.237                          0.584   0.020                                                              
  Lymphatic invasion (invasion vs no invasion)          1.319              0.359                                                                     1.109   0.148                                                              
  Venous invasion (no invasion vs invasion)             0.927              0.830                                                                     0.603   0.311                                                              
  GSE26193 cohort (n = 79)                                                                                                                                                                                                      
  Eight-gene signature (low-risk vs high-risk)          0.564              0.028                             0.552    0.023                                                                  0.599   0.044      0.553   0.021   
  Tumor grade (G1-G2 vs G3-G4)                          0.877              0.351                                                                                                             1.054   0.719                      
  FIGO stage (stage III-IV vs stage I-II)               1.699              0.006                             1.713    0.005                                                                  1.827   0.001      1.883   0.001   
  GSE51088 cohort (n = 106)                                                                                                                                                                                                     
  Eight-gene signature (low-risk vs high-risk)          0.624              0.035                             0.556    0.021                                                                                                     
  Age (old age vs young age)                            1.023              0.012                             1.008    0.148                                                                                                     
  Tumor grade (G3-G4 vs G1-G2)                          1.235              0.194                                                                                                                                                
  FIGO stage (stage III-IV vs stage I-II)               1.799              0.023                                                                                                                                                
  Disease status (not free vs free)                     60.734             \<0.001                           66.097   \<0.001                                                                                                   

HR: hazard ratio

###### 

Gene mutation status in serous ovarian cancer according to the autophagy-related signature.

  --------------------------------------------------------------
  Characteristics   High-risk\    Low-risk\     *p*-value     
                    (n = 130)     (n = 163)                   
  ----------------- ------------- ------------- ------------- --
  *BRCA1*                                       0.0359        

                    mutation      9 (6.9%)      24 (14.7%)    

  no mutation       121 (93.1%)   139 (85.3%)                 

  *BRCA2*                                       0.0691        

                    mutation      9 (6.9%)      22 (13.5%)    

  no mutation       121 (93.1%)   141 (86.5%)                 

  *BRCA1/2*                                     0.0062        

                    mutation      18 (13.8%)    44 (27.0%)    

  no mutation       112 (86.2%)   119 (73.0%)                 

  *CSMD3*                                       0.5995        

                    mutation      10 (7.7%)     10 (6.1%)     

                    no mutation   120 (92.3%)   153 (93.9%)   

  *FAT3*                                        0.3241        

                    mutation      10 (7.7%)     8 (4.9%)      

                    no mutation   120 (92.3%)   155 (95.1%)   

  *HMCN1*                                       0.5481        

                    mutation      8 (6.2%)      13 (8.0%)     

                    no mutation   122 (93.8%)   150 (92.0%)   

  *MUC16*                                       0.1612        

                    mutation      7 (5.4%)      16 (9.8%)     

                    no mutation   123 (94.6%)   147 (90.2%)   

  *RYR2*                                        0.7849        

                    mutation      7 (5.4%)      10 (6.1%)     

                    no mutation   123 (94.6%)   153 (93.9%)   

  *TP53*                                        0.2953        

                    mutation      125 (96.2%)   160 (98.2%)   

                    no mutation   5 (3.8%)      3 (1.8%)      

  *TTN*                                         0.0884        

                    mutation      22 (16.9%)    41 (25.2%)    

                    no mutation   108 (83.1%)   122 (74.8%)   

  *USH2A*                                       0.3178        

                    mutation      12 (9.2%)     10 (6.1%)     

                    no mutation   118 (90.8%)   153(93.9%)    
  --------------------------------------------------------------
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